Moreover, we also conducted preliminary in vitro assays to evaluate the efficacy of Anlotinib and in combination with osimertinib in EGFR T790M‐mutant osimertinib‐resistant NSCLC cell line H1975OR. This evidence concerns the gene EGFR and non-small cell lung carcinoma.